Vistin Pharma ASA is a Norway-based holding company, which operates through its subsidiary Vistin Pharma AS. The Company is engaged in the pharmaceuticals industry. The Company is a producer and supplier of Active Pharmaceutical Ingredients (APIs), which are used in medications for diabetes. Vistin Pharma offering such products: Metformin HCl (API); Metformin DC (direct compressible granules); Customized Particle Distribution (PSD) and Premix (Metformin + MgSt, can be delivered on-request). The Companyâ€™s customers are pharmaceutical companies worldwide.

Employees

Sector

Pharmaceuticals

Calendar

11-24 Ex-dividend date for special dividend - 0.5 NOK

More about the company

Quotes

Date	Price	Change	Volume
03/11/26	NOK 18.40	-1.08%	1,918
02/11/26	NOK 18.60	+1.09%	6,207
30/10/26	NOK 18.40	-1.08%	26,829
29/10/26	NOK 18.60	+1.92%	17,650
28/10/26	NOK 18.25	+0.27%	28,966

Real-time Oslo Bors

More quotes

Market Closed - Oslo Bors 18:45:00 03/11/2026 +03			5-day change	1st Jan Change
18.40 ^NOK	-1.08%		+1.10%	-11.54%

10-29	Vistin Pharma ASA, Q3 2026 Earnings Call, Oct 29, 2026
10-29	Vistin Pharma Asa Resolves to Pay Cash Dividend, Payable on or About 27 November 2026	CI

Market Cap	825M 88.92M 79.39M 72.85M 66.27M 124M 8.42B 127M 870M 351M 4.44B 334M 327M 14.03B	P/E 2024	16.7x	P/E 2025	12.3x
Enterprise Value	810M 87.31M 77.95M 71.53M 65.07M 122M 8.27B 124M 854M 344M 4.36B 328M 321M 13.78B	EV / Sales 2024	2.42x	EV / Sales 2025	2.01x
Free-Float	38.84%	Yield 2024	5.27%	Yield 2025	7.21%

Markets		Quality
Oslo Bors	VISTN	Real-time
CBOE	VISTIo	Real-time
Nasdaq Stockholm	VISTNO	Delayed
Börse Stuttgart	VP4	Delayed
CBOE	0RAM	Real-time
Deutsche Boerse AG	VP4	Delayed

10-29	Vistin Pharma ASA, Q3 2026 Earnings Call, Oct 29, 2026
10-29	Vistin Pharma Asa Resolves to Pay Cash Dividend, Payable on or About 27 November 2026	CI
10-29	Vistin Pharma ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI
08-20	Vistin Pharma ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-20	Vistin Pharma ASA, Q2 2026 Earnings Call, Aug 20, 2026
04-24	Vistin Pharma ASA Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-24	Vistin Pharma ASA, Q1 2026 Earnings Call, Apr 24, 2026
04-24	Vistin Pharma Q1 net profit of NOK 21.5 mln	RE
02-12	Vistin Pharma preliminary Q4 ebitda at NOK 26 mln	RE
02-12	Vistin Pharma ASA, Q4 2025 Earnings Call, Feb 12, 2026
02-12	Vistin Pharma ASA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-12	Vistin Pharma ASA Proposes Ordinary Cash Dividend for 2025, Payable on or About 29 May 2026 and November 2026 Respectively	CI
31/10/25	Vistin Pharma ASA Reports Production Results for the Third Quarter Ended September 30, 2025	CI

Vistin Pharma ASA Stock

Stocks

VISTN

NO0010734122

Pharmaceuticals

Valuation: Vistin Pharma ASA

Chart: Vistin Pharma ASA

Latest news: Vistin Pharma ASA

Last Transcript: Vistin Pharma ASA

Press Releases: Vistin Pharma ASA

Quotes and Performance

Price Extremes

Managers and Directors: Vistin Pharma ASA

Latest insider transactions

Generic Pharmaceuticals

Financials

Company Profile

Quotes

10-29	Vistin Pharma ASA (VISTN): Key information relating to the cash dividend	GL
10-29	Vistin Pharma ASA: Third quarter and YTD 2026 financial results	GL
10-21	Vistin Pharma ASA: Invitation to Q3 2026 conference call	GL
08-20	Vistin Pharma ASA: Second quarter and YTD 2026 financial results	GL
08-13	Vistin Pharma ASA: Invitation to Q2 2026 conference call	GL

1 day	-1.08%
1 week	+1.10%
1 month	+0.82%
3 months	-7.54%
6 months	-18.58%
Current year	-11.54%

1 week	17.9	18.85
1 month	17.8	18.85
Current year	17.7	23.5
1 year	17.7	23.5
3 years	17.7	28.8
5 years	11.25	28.8
10 years	5	29.45

Manager	Title	Age	Since
Magnus Tolleshaug CEO	Chief Executive Officer	-	01/01/2024
Alexander Karlsen DFI	Director of Finance/CFO	-	02/03/2020
Vegard Heggem COO	Chief Operating Officer	-	-

Director	Title	Age	Since
Bettina Banoun BRD	Director/Board Member	54	08/05/2018
Espen Lia Gregoriussen BRD	Director/Board Member	-	01/01/2017
Kari Eian Krogstad BRD	Director/Board Member	62	01/01/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/18/23 A	SAGA PURE ASA	Buy	Company	100,000	0.2255%
5/31/23 A	Magnus Tolleshaug	Buy	Chief Executive Officer	15,000	0.0338%
5/30/23 A	Øystein Stray Spetalen	Buy	Director	250,000	0.5638%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VISTIN PHARMA ASA	-1.08%	+1.10%	-14.42%	-19.30%	88.92M
ELI LILLY AND COMPANY	+0.86%	+10.84%	+58.49%	+150.24%	1,257B
JOHNSON & JOHNSON	-0.75%	+0.11%	+44.44%	+77.77%	651B
ABBVIE INC.	-0.07%	+0.79%	+36.18%	+104.10%	510B
ROCHE HOLDING AG	-1.56%	-2.01%	+50.67%	+64.81%	388B
MERCK & CO., INC.	-1.99%	+2.48%	+76.18%	+40.58%	366B
NOVARTIS AG	-0.02%	+2.11%	+32.16%	+57.79%	303B
ASTRAZENECA PLC	-0.72%	+7.32%	+11.29%	+33.98%	288B
AMGEN INC.	-0.23%	+3.60%	+56.62%	+71.97%	252B
GILEAD SCIENCES, INC.	-0.18%	+6.84%	+39.25%	+108.31%	211B
Average	-0.52%	+4.41%	+39.09%	+69.02%	422.67B
Weighted average by Cap.	-0.22%	+5.30%	+48.26%	+94.85%

	2024	2025
Net sales	430M 46.3M 41.34M 37.94M 34.51M 64.7M 4.38B 65.99M 453M 183M 2.31B 174M 170M 7.31B	452M 48.76M 43.53M 39.95M 36.34M 68.13M 4.62B 69.49M 477M 192M 2.44B 183M 179M 7.7B
Net income	62.75M 6.76M 6.04M 5.54M 5.04M 9.45M 640M 9.64M 66.2M 26.68M 338M 25.39M 24.85M 1.07B	74.75M 8.06M 7.19M 6.6M 6.01M 11.26M 763M 11.48M 78.86M 31.79M 403M 30.25M 29.6M 1.27B
Net Debt	-10.55M -1.14M -1.02M -932K -848K -1.59M -108M -1.62M -11.13M -4.49M -56.83M -4.27M -4.18M -180M	-14.91M -1.61M -1.43M -1.32M -1.2M -2.25M -152M -2.29M -15.73M -6.34M -80.31M -6.03M -5.9M -254M